233 related articles for article (PubMed ID: 23797290)
21. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
23. High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.
Kozlowski P; Åström M; Ahlberg L; Bernell P; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Amini RM; Hallböök H;
Eur J Haematol; 2014; 92(5):377-81. PubMed ID: 24443846
[TBL] [Abstract][Full Text] [Related]
24. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Thomas DA; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister FB; Cabanillas FF; Murphy S; Keating MJ; Kantarjian H
J Clin Oncol; 1999 Aug; 17(8):2461-70. PubMed ID: 10561310
[TBL] [Abstract][Full Text] [Related]
25. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
Gill S; Lane SW; Crawford J; Cull G; Joske D; Marlton P; Mollee PN; Prince HM; Seymour JF
Ann Hematol; 2008 Sep; 87(9):727-34. PubMed ID: 18401583
[TBL] [Abstract][Full Text] [Related]
26. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
Thomas D; O'Brien S; Faderl S; Ravandi F; Jabbour E; Pierce S; Cortes J; Kantarjian H
Cancer; 2010 Oct; 116(19):4580-9. PubMed ID: 20572037
[TBL] [Abstract][Full Text] [Related]
27. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
[TBL] [Abstract][Full Text] [Related]
28. Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.
Landsburg DJ; Stadtmauer E; Loren A; Goldstein S; Frey N; Nasta SD; Porter DL; Tsai DE; Perl AE; Hexner EO; Luger S
Am J Hematol; 2013 Aug; 88(8):657-60. PubMed ID: 23640768
[TBL] [Abstract][Full Text] [Related]
29. Progressive paresthesia and weakness after intrathecal chemotherapy.
Marshall R; Gupta ND; Palacios E; Neitzschman HR
J La State Med Soc; 2008; 160(2):92-4. PubMed ID: 18681351
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
Ramos-Peñafiel CO; Cabrera-García Á; Rozen-Fuller E; González-León G; Balderas C; Kassack-Ipiña JJ; Castellanos-Sinco H; Martínez-Murillo C; Montaño-Figueroa E; Martínez-Tovar A; Olarte-Carrillo I; Santoyo-Sánchez A; Collazo-Jaloma J
Rev Peru Med Exp Salud Publica; 2014; 31(3):525-9. PubMed ID: 25418653
[TBL] [Abstract][Full Text] [Related]
31. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
Alduaij A; Butera JN; Treaba D; Castillo J
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
[TBL] [Abstract][Full Text] [Related]
32. [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007].
Arteaga-Ortiz L; Buitrón-Santiago N; Rosas-López A; Rosas-Arzate G; Armengolt-Jiménez A; Aguayo A; López-Karpovitch X; Crespo-Solís E
Rev Invest Clin; 2008; 60(6):459-69. PubMed ID: 19378832
[TBL] [Abstract][Full Text] [Related]
33. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.
Keane C; Gibbs S; Seymour JF; Mills AK; Grimmett K; Van Kuilenberg R; Saal R; Gill D; Prince HM; Marlton P; Mollee P
Hematol Oncol; 2006 Sep; 24(3):159-63. PubMed ID: 16775841
[TBL] [Abstract][Full Text] [Related]
34. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
[TBL] [Abstract][Full Text] [Related]
35. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
[TBL] [Abstract][Full Text] [Related]
36. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Verma D; O'Brien S; Thomas D; Faderl S; Koller C; Pierce S; Kebriaei P; Garcia-Manero G; Cortes J; Kantarjian H; Ravandi F
Cancer; 2009 Jan; 115(1):101-6. PubMed ID: 19090005
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
Vu K; Busaidy N; Cabanillas ME; Konopleva M; Faderl S; Thomas DA; O'Brien S; Broglio K; Ensor J; Escalante C; Andreeff M; Kantarjian H; Lavis V; Yeung SC
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):355-62. PubMed ID: 22658895
[TBL] [Abstract][Full Text] [Related]
38. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H
Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
40. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Benton CB; Thomas DA; Yang H; Ravandi F; Rytting M; O'Brien S; Franklin AR; Borthakur G; Dara S; Kwari M; Pierce SR; Jabbour E; Kantarjian H; Garcia-Manero G
Br J Haematol; 2014 Nov; 167(3):356-65. PubMed ID: 25066676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
